Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Target Price at $14.56

Inozyme Pharma, Inc. (NASDAQ:INZY) has earned a consensus rating of “Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last year is $14.56.

Several equities research analysts have issued reports on the company. Wedbush restated an “outperform” rating and set a $7.00 price objective (down from $12.00) on shares of Inozyme Pharma in a report on Monday, March 10th. Wells Fargo & Company reduced their price objective on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Raymond James lowered their target price on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a research note on Wednesday, March 12th. Needham & Company LLC reduced their price target on shares of Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Inozyme Pharma in a report on Tuesday, March 11th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Harvest Investment Services LLC bought a new position in shares of Inozyme Pharma in the fourth quarter worth $31,000. Graham Capital Management L.P. acquired a new stake in Inozyme Pharma in the fourth quarter worth about $33,000. China Universal Asset Management Co. Ltd. bought a new position in Inozyme Pharma in the 4th quarter valued at about $38,000. D. E. Shaw & Co. Inc. bought a new position in Inozyme Pharma in the 4th quarter valued at about $49,000. Finally, ProShare Advisors LLC acquired a new position in Inozyme Pharma during the 4th quarter valued at about $49,000. 88.30% of the stock is owned by institutional investors and hedge funds.

Inozyme Pharma Trading Down 7.5 %

NASDAQ:INZY opened at $0.92 on Wednesday. The stock has a market cap of $59.10 million, a price-to-earnings ratio of -0.59 and a beta of 1.32. Inozyme Pharma has a one year low of $0.91 and a one year high of $7.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The business’s 50-day simple moving average is $1.22 and its 200 day simple moving average is $2.90.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.